Quick Answer
Bluejay Diagnostics, Inc. reported Diluted EPS of $15.25 per share (loss) for fiscal year 2025.
Bluejay Diagnostics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$15.25 | +96.7% |
| 2024 | -$456.75 | +87.4% |
| 2023 | -$3631.48 | -39287.0% |
| 2022 | -$9.22 | -2148.8% |
| 2021 | -$0.41 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.01 | +98.7% | +28.4% |
| June 30, 2025 | -$1.41 | +99.4% | +58.2% |
| March 31, 2025 | -$3.37 | +99.1% | +95.6% |
| September 30, 2024 | -$76.94 | -361.5% | +70.0% |
| June 30, 2024 | -$256.16 | -1064.4% | +35.1% |
| March 31, 2024 | -$394.76 | -15753.8% | -2268.1% |
| September 30, 2023 | -$16.67 | -467.0% | +24.2% |
| June 30, 2023 | -$22.00 | -1000.0% | -783.5% |
- Bluejay Diagnostics, Inc. showed an increase of +96.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Bluejay Diagnostics, Inc.’s diluted eps has declined by 3619.5% (from $0.41 per share (loss) to $15.25 per share (loss)).
- The most recent figure is from Bluejay Diagnostics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: